YWYi-Ching Wang

Yi-Ching Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yi-Ching Wang has a total of 30 co-authors. Here are the top co-authors by number of shared publications:

  • Chih‐Yi Chen

    Department of Thoracic Surgery, Veterans General Hospital, Taichung, Taiwan

    2 shared publications
  • Chuen-Ming Shih

    Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical College Hospital and Institute of Medicine, Chung Shan Medical University, Taichung, Republic of China

    2 shared publications
  • Jung‐Ta Chen

    Department of Pathology, Veterans General Hospital, Taichung, Taiwan

    2 shared publications
  • Ruo‐Chia Tseng

    Department of Life Sciences, National Taiwan Normal University, Taipei, Taiwan

    2 shared publications
  • Chih-Yi Chen

    Division of Thoracic Surgery, Taichung Veterans General Hospital, Taichung; and

    1 shared publication
  • Chin-Chu Lee

    Department of Biology, National Taiwan Normal University, Taipei, Taiwan, ROC

    1 shared publication

Latest Publications

  • Open Access

    Genomewide loss of heterozygosity and its clinical associations in non small cell lung cancer

    by Ruo‐Chia Tseng, Jer‐Wei Chang, Feng‐Jen Hsien, Ya‐Hui Chang, Chin‐Fu Hsiao, Jung‐Ta Chen, Chih‐Yi Chen, Yuh‐Shan Jou, Yi‐Ching Wang

    We extensively allelotyped a panel of 71 microdissected primary surgically resected non small cell lung cancer (NSCLC) tumors to identify chromosomal regions that are likely to contain tumor suppressor genes (TSGs) or associated with clinicopathologic and prognostic effects. Loss of heterozygosity (LOH) was detected by genotyping of 177 microsatellite markers and correlation of LOH with clinicopathologic parameters and prognosis was analyzed. Twenty markers showed an LOH frequency greater than 48%, and 8 of them (2p23.3, 2p24.3, 2q35, 6p22.2, 7p14.3, 7p22.2, 17q24.3 and 21q22.3) were novel in NSCLC. The high LOH regions were confirmed by further aligning continuous LOH regions from another set of 24 NSCLC tissues and defining 7 minimal deletion regions ranging from 1.29 to 12.26 cM. The aberrations of 8 markers showed a significant correlation with alteration of p16 and Rb proteins, suggesting the gene(s) located in the chromosomal loss that may interact with p16/Rb pathway. In addition, markers specifically associated with smoking, histology types and tumor stages were identified and the linked candidate TSGs were suggested. For example, marker D1S1612 closely linked with Mig‐6 gene was associated with smoking patients, squamous cell carcinoma patients and late‐stage patients. Furthermore, 3 markers, D2S2968, D6S2439 and D7S1818, were significantly associated with poor prognosis of NSCLC patients using both univariate and multivariate Cox's regression analyses (p = 0.035, 0.022 and 0.006, respectively). These markers can potentially be used for early lung cancer detection, outcome measurement and the positional cloning of new TSGs whose loss of function contributes to NSCLC tumorigenesis.


  • Open Access

    CpG Island Methylation Is Responsible for p14ARF Inactivation and Inversely Correlates with p53 Overexpression in Resected Non–Small Cell Lung Cancer

    by Han-Shui Hsu, Yu-Chien Wang, Ruo-Chia Tseng, Jer-Wei Chang, Jung-Ta Chen, Chuen-Ming Shih, Chih-Yi Chen, Yi-Ching Wang

    Purpose and Experimental Design: The molecular mechanisms by which the p14ARF gene is altered in non–small cell lung cancer (NSCLC) are complex and unclear. Using genetic and epigenetic analyses, we examined various molecular alterations including the loss of protein and mRNA expression, and 5′CpG hypermethylation, allelic imbalance, and mutation of the p14ARF gene in a series of 102 NSCLC samples, in parallel with clinicopathological and prognostic analyses. To clarify the biological significance of p14ARF alterations, its relationship with p16INK4a and p53 alterations was also examined. Results: We found that 34% of NSCLC patients had aberrant P14ARF protein expression, which was more frequent in adenocarcinomas (AD; 44%) than in squamous cell carcinomas (22%; P = 0.024). A high concordance was observed between alterations in protein and mRNA expression and 5′CpG hypermethylation (P ≤ 0.001). The p14ARF hypermethylation inversely correlated with P53 overexpression (P = 0.001). This mutually exclusive relationship for alteration between p14ARF and p53 was also supported by a worse prognosis of AD patients with positive P14ARF expression (P = 0.01) and of AD patients with P53 overexpression (P = 0.006). Our data also indicated that hemizygous/homozygous deletion and mutation in the p14ARF gene occurred at 26%, 9%, and 0%, respectively, of microdissected NSCLCs. Conclusions: Our data suggest that p14ARF 5′CpG hypermethylation is the predominant mechanism involved in the aberrant expression of the p14ARF gene. In addition, p14ARF 5′CpG hypermethylation occurs inversely to P53 overexpression.


  • Damage formation and repair efficiency in the p53 gene of cell lines and blood lymphocytes assayed by multiplex long quantitative polymerase chain reaction

    by Yu-Chieh Wang, Pei-Jung Lee, Chuen-Ming Shih, Hsing-Yu Chen, Chin-Chu Lee, Yuan-Yen Chang, Yu-Ting Hsu, Ying-Ju Liang, Li-Ya Wang, Wen-Hua Han, et al.


  • Open Access

    Alterations of the p16ink4a gene in resected nonsmall cell lung tumors and exfoliated cells within sputum

    by Jung‐Ta Chen, Yi‐Chun Chen, Yu‐Chien Wang, Ruo‐Chia Tseng, Chih‐Yi Chen, Yi‐Ching Wang

    Recently, we reported that p16 protein expression was nondetectable in 49.5% of 107 resected nonsmall cell lung cancers (NSCLCs), suggesting that the p16INK4a gene is frequently inactivated in primary NSCLC. To identify the molecular basis for this p16 immunohistochemical negativity further, we performed a genetic and epigenetic study of p16INK4a status in a series of 115 NSCLC samples parallel to the clinicopathologic and prognostic analyses. Microdissected tumor DNA samples were screened for homozygous deletion using comparative multiplex‐polymerase chain reaction (PCR), for intragenic mutation using direct sequencing and for loss of heterozygosity (LOH) using an intragenic microsatellite marker, D9S942. Of these samples, 67 were further analyzed by SmaI‐based PCR methylation assay to evaluate aberrant methylation at the gene. To examine the correlation of aberrant methylation in tumor and sputum samples, sputum samples from 12 matched patients were assessed for this change. We found that methylation of the p16INK4a gene was present in 38 of the 67 (56.7%) tumors and was significantly associated with negative p16 protein expression (p = 0.029). A 92% (11/12) concordance of sputum samples with matched resected tumors was found. The survival rates among adenocarcinoma patients with p16INK4a methylation were lower, but at a level of borderline significance compared with those patients without methylation (p = 0.071). In addition, 29.4% of the informative cases were found to harbor LOH at D9S942. None of the 115 microdissected tumors exhibited homozygous deletion in the p16INK4a gene. Only 1 patient exhibited a complex mutation at the fourth ankyrin repeat consensus sequence and concordantly demonstrated p16 immunohistochemical negativity. Overall, 69% (79/115) of NSCLC tumors had at least 1 type of p16INK4a alteration. Our data provide compelling evidence that p16INK4a alterations are involved in NSCLC tumorigenesis and that promoter methylation is the predominant mechanism in p16INK4a deregulation.


  • Lack of Evidence of Association of p21WAF1/CIP1 Polymorphism with Lung Cancer Susceptibility and Prognosis in Taiwan

    by Chuen‐Ming Shih, Pey‐Tzy Lin, Hui‐Chun Wang, Wei‐Chi Huang, Yi‐Ching Wang

    An association between the Arg allele of the p21WAF1/CIP1 codon 31 polymorphism and lung cancer has been reported. However, the genotype distribution of the p21 codon 31 polymorphism, as well as the association of this polymorphism with lung cancer risk and prognosis, remain undefined in the Taiwanese population. Therefore, we investigated the genotype distribution of the p21 codon 31 polymorphism in 155 lung cancer patients and 189 non‐cancer controls. The genotype frequencies in the Taiwanese non‐cancer controls were 0.51 (Ser) and 0.49 (Arg). χ2 analysis indicated significant differences in Taiwanese genotype distribution of p21 from those reported for Swedes (P=0.001), Caucasians (P=0.001), Indians (P=0.001), and African‐Americans (P=0.001). However, our data did not demonstrate an association of the Arg allele of the p21 polymorphism with lung cancer risk in Taiwan. Lung cancer patients with Ser/Arg and Arg/Arg genotypes were at a nonsignificant 1.15‐fold increased risk of lung cancer when compared to individuals with the Ser/Ser genotype (95%CI, 0.70–1.86). In addition, although p21 is a downstream target of p53, we found no significant correlation of the p21 polymorphism with the p53 polymorphism and p53 gene mutation in lung cancer patients. We further investigated the association of the p21 polymorphism with prognosis in 154 lung cancer patients. Patients with the Ser/Ser genotype tended to have a poorer prognosis than those with the Ser/Arg and Arg/Arg genotypes (P=0.097, by the log rank test). Our data suggest that the p21 codon 31 polymorphism may not play a significant role in cancer susceptibility and the prognosis of lung cancer patients in Taiwan.